SCHEMBL1932043

SCHEMBL1932043

CCC(O)C1CCCCN1

nearest known ligand 0.50

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
SLC6A2 P23975 4/20 0.46
SLC6A4 P31645 4/20 0.46
SLC6A3 Q01959 4/20 0.46
HIF1A Q16665 1/20 0.41
HSD17B10 Q99714 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3478050 1.00 SLC6A2 (0.46) SLC6A2SLC6A4SLC6A3HIF1AHSD17B10
SCHEMBL1225120 1.00 SLC6A2 (0.46) SLC6A2SLC6A4SLC6A3HIF1AHSD17B10
SCHEMBL1225118 1.00 SLC6A2 (0.46) SLC6A2SLC6A4SLC6A3HIF1AHSD17B10
SCHEMBL13510425 1.00 SLC6A2 (0.46) SLC6A2SLC6A4SLC6A3HIF1AHSD17B10
SCHEMBL31048385 0.98 SLC6A2 (0.45) SLC6A2SLC6A4SLC6A3HIF1AHSD17B10
SCHEMBL25446671 0.94
SCHEMBL3696352 0.94
SCHEMBL2647260 0.94
SCHEMBL5053538 0.94
SCHEMBL2646374 0.94

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12569679-B2 Treatment delivery system WearOptimo Pty Ltd (AU) 2026-03-10 US disclosed
US-12484814-B2 Actuator system WearOptimo Pty Ltd (AU) 2025-12-02 US disclosed
US-20250025078-A1 ELECTRODE ARRANGEMENT WearOptimo Pty Ltd (AU) 2025-01-23 US disclosed
CN-116747255-A Cannabis pain-relieving gel and preparation method thereof 黑龙江钲拓农业发展有限公司 2023-09-15 CN disclosed
US-20230053962-A1 ANALYTE MEASUREMENT SYSTEM WearOptimo Pty Ltd (AU) 2023-02-23 US disclosed
US-20230035892-A1 METHODS AND COMPOSITIONS FOR TREATING CANCER FLAGSHIP PIONEERING, INC. 2023-02-02 US disclosed
US-20220346679-A1 ANALYTE MEASUREMENT SYSTEM WearOptimo Pty Ltd (AU) 2022-11-03 US disclosed
EP-4037552-A1 ANALYTE MEASUREMENT SYSTEM Wearoptimo Pty Ltd (AU) 2022-08-10 EP disclosed
US-11274158-B2 Methods and compositions for treating inflammatory or autoimmune diseases or conditions using calcitonin receptor activators FLAGSHIP PIONEERING INNOVATIONS V, INC. (US) 2022-03-15 US disclosed
US-20220033490-A1 METHODS AND COMPOSITIONS FOR TREATING CANCER USING CHRNA6 INHIBITORS FLAGSHIP PIONEERING INNOVATIONS V INC (US) 2022-02-03 US disclosed
US-8581178-B2 Combined mass and differential mobility spectrometry and associated methods, systems, and devices DH TECHNOLOGIES DEVELOPMENT PTE. LTD. (SG) 2013-11-12 US disclosed
US-8384024-B2 Tandem differential mobility spectrometers and mass spectrometer for enhanced analysis DH TECHNOLOGIES DEVELOPMENT PTE. LTD. (SG) 2013-02-26 US disclosed
US-20110133076-A1 TANDEM DIFFERENTIAL MOBILITY SPECTROMETERS AND MASS SPECTROMETER FOR ENHANCED ANALYSIS MILLER RAANAN A 2011-06-09 US disclosed
WO-2010131058-A1 PRODUCT FOR THE PROTECTION AGAINST HONEYBEE MITES, AND METHOD FOR THE PREPARATION OF THE ACTIVE SUBSTANCE VON BARTHELDNE ABRI JUDIT (HU) 2010-11-18 WO disclosed
US-7812305-B2 Tandem differential mobility spectrometers and mass spectrometer for enhanced analysis SIONEX CORPORATION (US) 2010-10-12 US disclosed
US-20100048893-A1 Substituted arylalkanoic acid derivatives and use thereof ASAHI KASEI PHARMA CORPORATION (JP) 2010-02-25 US disclosed
US-20080149824-A1 Tandem differential mobility spectrometers and mass spectrometer for enhanced analysis DH TECHNOLOGIES DEVELOPMENT PTE. LTD. (SG) 2008-06-26 US disclosed
US-20060289745-A1 Combined mass and differential mobility spectrometry and associated methods, systems, and devices DH TECHNOLOGIES DEVELOPMENT PTE. LTD. (SG) 2006-12-28 US disclosed
US-4752554-A Optical information recording medium RICOH CO., LTD. (JP) 1988-06-21 US disclosed
EP-0143992-A1 Optical information recording medium Ricoh Company, Ltd (JP) 1985-06-12 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220033490-A1 METHODS AND COMPOSITIONS FOR TREATING CANCER USING CHRNA6 INHIBITORS CHRNA6, CHRNA1, CHRNB1 SLC6A2 189/4885SLC6A4 510/4885SLC6A3 509/4885
US-20100048893-A1 Substituted arylalkanoic acid derivatives and use thereof CYSLTR1, CYSLTR2, LTB4R2 SLC6A2 3092/4885SLC6A4 1621/4885SLC6A3 2005/4885
US-12569679-B2 Treatment delivery system PIEZO1, DSG1, KRT18 SLC6A2 345/4885SLC6A4 575/4885SLC6A3 1967/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.